Source:http://linkedlifedata.com/resource/pubmed/id/18413856
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2008-6-19
|
pubmed:abstractText |
The present study investigated whether beta3-adrenoceptor activation acts on the bladder afferent pathway by examination of the visceromotor reflex (VMR) and pressor responses to urinary bladder distension (UBD) and whether beta3-adrenoceptor activation produces urinary bladder relaxation in hyperactive spontaneously hypertensive rats (SHRs) in comparison with their normotensive control rats [Wistar-Kyoto (WKY)]. Using the VMR responses to noxious UBD as a measure of bladder afferent signal transmission, SHRs did not present a sensitized bladder phenotype. However, reduced bladder compliance accompanied by a reduced void threshold was detected in the SHR detrusor. Furthermore, the selective beta3-adrenoceptor agonist disodium 5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL-316243) (i.v.) failed to attenuate VMR or pressor responses to UBD in either SHRs or WKY rats, but it dose-dependently inhibited rhythmic contraction (RC) in SHRs. The minimal effective dose was 0.001 mg/kg. Using the same model in WKY rats, CL-316243 did not elicit significant inhibition of contractions in the bladder RC assay. These results suggest that SHRs represent abnormal efferent/detrusor function (detrusor overactivity) without mechanosensory afferent hypersensitivity. The beta3-adrenoceptor agonist CL-316243 acts on the detrusor muscle to increase urine storage in SHRs.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
1521-0103
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
326
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
178-85
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:18413856-Adrenergic beta-3 Receptor Agonists,
pubmed-meshheading:18413856-Animals,
pubmed-meshheading:18413856-Dioxoles,
pubmed-meshheading:18413856-Female,
pubmed-meshheading:18413856-Muscle Contraction,
pubmed-meshheading:18413856-Rats,
pubmed-meshheading:18413856-Rats, Inbred SHR,
pubmed-meshheading:18413856-Rats, Inbred WKY,
pubmed-meshheading:18413856-Receptors, Adrenergic, beta-3,
pubmed-meshheading:18413856-Urinary Bladder,
pubmed-meshheading:18413856-Urinary Bladder, Overactive,
pubmed-meshheading:18413856-Urination
|
pubmed:year |
2008
|
pubmed:articleTitle |
Effects of the beta 3-adrenergic receptor agonist disodium 5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL-316243) on bladder micturition reflex in spontaneously hypertensive rats.
|
pubmed:affiliation |
Department of Urology, GlaxoSmithKline Pharmaceuticals, 709 Swedeland Rd., King of Prussia, PA 19406-0939, USA.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|